GGrantIndex
← Search

TRIAL OF BRYOSTATIN 1 GIVEN AS CONTINUOUS INFUSION IN CANCER PATIENTS

$0M01FY2002RRNIH

Johns Hopkins University, Baltimore MD

Investigators

Linked publications & trials

Abstract

This protocol is to determine the safety and toxicity of bryostatin 1 given as a brief or continuous infusion in cancer patients every 21 days, to evaluate the pharmacokinetcic parameters of byrostatin 1 in this patient population. As no assay exists for this drug, several bioassays will be evaluated in this study. The study is looking for preliminary evidence of therapeutic activity of pharmacokinetic assay of bryostatin 1 activity.

View original record on NIH RePORTER →